Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100
Go back to Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100| (NYSE: ANRO) | Delayed: 30.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.27 | 52 Week High | $ | |||
| Open | $30.27 | 52 Week Low | $ | |||
| Day High | $30.27 | P/E | N/A | |||
| Day Low | $30.27 | EPS | $ | |||
| Volume | 70 | |||||

